BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025

The ɑ-emitting radioisotope’s rapid decay has logistical drawbacks, but its supply could beat actinium-225’s on scale

A focus on first-in-class innovation and solid tumor applications

The radiotherapy is one of multiple modalities J&J is testing against KLK2, which could enable tumor-specific targeting across prostate cancer stages

Data science deals, expanded pipeline diversity define Mathai Mammen’s five years as pharmaceuticals R&D leader at J&J

How WuXi NextCode is honing its AI tools through academic collaborations

New Israel Biotech Fund leverages experienced advisory board for investments